Last reviewed · How we verify
LNK01004 ointment 1.0%
LNK01004 ointment 1.0% is a Small molecule drug developed by Lynk Pharmaceuticals Co., Ltd. It is currently in Phase 2 development.
At a glance
| Generic name | LNK01004 ointment 1.0% |
|---|---|
| Sponsor | Lynk Pharmaceuticals Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of LNK01004 Ointment in Adults With Atopic Dermatitis (PHASE2)
- Safety, Tolerability and Pharmacokinetics of LNK01004 Ointment in Adults With Atopic Dermatitis. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LNK01004 ointment 1.0% CI brief — competitive landscape report
- LNK01004 ointment 1.0% updates RSS · CI watch RSS
- Lynk Pharmaceuticals Co., Ltd portfolio CI
Frequently asked questions about LNK01004 ointment 1.0%
What is LNK01004 ointment 1.0%?
LNK01004 ointment 1.0% is a Small molecule drug developed by Lynk Pharmaceuticals Co., Ltd.
Who makes LNK01004 ointment 1.0%?
LNK01004 ointment 1.0% is developed by Lynk Pharmaceuticals Co., Ltd (see full Lynk Pharmaceuticals Co., Ltd pipeline at /company/lynk-pharmaceuticals-co-ltd).
What development phase is LNK01004 ointment 1.0% in?
LNK01004 ointment 1.0% is in Phase 2.
Related
- Manufacturer: Lynk Pharmaceuticals Co., Ltd — full pipeline
- Compare: LNK01004 ointment 1.0% vs similar drugs
- Pricing: LNK01004 ointment 1.0% cost, discount & access